Holista Colltech Limited (HCT) AI Stock Analysis

• Market Cap: AU$33.11M
• Dividend Yield: N/A
• Average Volume (3M): 72.05K
• Price to Earnings (P/E): 39.1
• Beta (1Y): -0.37
• Revenue Growth: 6.76%
• EPS Growth: N/A
• Country: AU
• Employees: 3
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 367,834,350
• 10 Day Avg. Volume: 123,924
• 30 Day Avg. Volume: 72,050
• PEG Ratio: 0.44
• Price to Book (P/B): -2.10
• Price to Sales (P/S): 0.65
• P/FCF Ratio: -3.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: AU$0.08 ▼(-8.89% Downside)

Holista Colltech Limited's overall stock score is primarily impacted by its poor financial performance, marked by declining revenues, negative equity, and cash flow inefficiencies. Technical analysis shows bearish momentum, although the stock is oversold, which might attract some buyers. The high P/E ratio suggests overvaluation, and the lack of dividend yield may reduce its appeal to certain investors.

Positive Factors

Product Innovation

The focus on patented technologies and natural ingredients positions Holista Colltech as an innovator in health and wellness, potentially driving long-term demand and market differentiation.

Strategic Partnerships

Partnerships with global distributors and research institutions enhance market reach and product development, supporting sustainable growth and competitive positioning.

Gross Profit Margin

A reasonable gross profit margin indicates the company's ability to maintain cost efficiency and pricing power, which is crucial for long-term profitability.

Negative Factors

Declining Revenue

The declining revenue trend poses a risk to the company's growth prospects and may challenge its ability to sustain operations and invest in future opportunities.

Negative Equity

Negative equity indicates financial instability, limiting the company's ability to raise capital and invest in growth, potentially leading to insolvency risks.

Cash Flow Challenges

Persistent negative cash flow reflects operational inefficiencies and challenges in converting revenue into cash, impacting the company's financial flexibility and sustainability.

Holista Colltech Limited Business Overview & Revenue Model

Company Description

Holista Colltech Limited (HCT) is an innovative biotechnology company based in Australia, specializing in the development and commercialization of natural health products and dietary supplements. The company operates primarily within the health and wellness sector, focusing on areas such as nutraceuticals, functional foods, and animal health products. HCT's core offerings include natural ingredients derived from collagen and other bioactive compounds aimed at promoting health, wellness, and enhancing quality of life.

How the Company Makes Money

Holista Colltech Limited generates revenue through multiple streams, primarily by selling its proprietary health and wellness products to consumers and businesses. The company has established key partnerships with distributors and retailers, enabling it to reach a broader market for its products. Additionally, HCT engages in contract manufacturing for third-party brands, which provides another significant source of income. The increasing global demand for natural and plant-based health solutions further contributes to the company's revenue, as it aligns with consumer trends towards healthier lifestyles.

Holista Colltech Limited Financial Statement Overview

Summary

Holista Colltech Limited is facing significant financial challenges. The income statement shows declining revenues and persistent net losses. The balance sheet reveals financial distress with negative equity, and cash flow statements indicate operational inefficiencies. Strategic measures are needed to stabilize financial health.

Income Statement

Holista Colltech Limited shows a volatile income statement with declining revenue and persistent net losses over the years. The gross profit margin for 2024 is approximately 50.03%, which is reasonable. However, the net profit margin remains negative due to continued net losses. Revenue has decreased from $8.2 million in 2022 to $5.6 million in 2024, indicating a negative growth trend.

Balance Sheet

The balance sheet reveals financial distress, with a negative stockholders' equity of -$1.73 million in 2024, leading to an unsustainable debt-to-equity ratio. The company's total debt has been increasing, while assets are declining, indicating a potential risk of insolvency. The equity ratio is negative due to the negative equity, highlighting financial instability.

Cash Flow

Cash flow statements indicate challenges, with negative operating cash flow and negative free cash flow persistently over the years. The free cash flow growth rate is negative, showing no improvement in cash generation. The operating cash flow to net income ratio is unfavorable, reflecting inefficiencies in converting revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.83M	5.60M	5.95M	8.24M	8.02M	7.11M
Gross Profit	2.88M	87.03K	370.06K	4.24M	1.31M	873.15K
EBITDA	911.32K	304.37K	-4.52M	-1.02M	-957.40K	-5.30M
Net Income	600.70K	-84.21K	-4.81M	-1.45M	-1.26M	-5.48M
Balance Sheet
Total Assets	3.55M	3.34M	3.35M	5.52M	6.93M	8.05M
Cash, Cash Equivalents and Short-Term Investments	41.75K	21.72K	59.77K	117.53K	1.21M	2.73M
Total Debt	1.73M	1.77M	1.57M	1.22M	890.32K	942.70K
Total Liabilities	5.65M	6.71M	6.74M	3.96M	3.95M	3.41M
Stockholders Equity	-528.53K	-1.73M	-1.97M	2.83M	4.10M	5.42M
Cash Flow
Free Cash Flow	-2.30M	-1.02M	-411.67K	-1.19M	-1.72M	-3.90M
Operating Cash Flow	-2.27M	-1.01M	-407.12K	-1.11M	-1.68M	-3.87M
Investing Cash Flow	684.57K	692.12K	-46.70K	-105.69K	50.35K	-80.75K
Financing Cash Flow	1.51M	143.75K	418.42K	120.85K	109.49K	6.58M

Holista Colltech Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HCT, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.09 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HCT.

Holista Colltech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MBH	54 Neutral	AU$38.08M	-1.61	-31.14%	―	-15.07%	29.45%
HCT	43 Neutral	AU$33.11M	39.13	―	―	6.76%	―
OMG	42 Neutral	AU$9.90M	-2.78	-77.48%	―	63.30%	70.00%
EVE	41 Neutral	AU$6.55M	-2.02	-60.84%	―	-18.70%	20.83%
WNX	38 Underperform	AU$7.00M	-0.20	-184.71%	―	39.53%	49.99%

Holista Colltech Limited Corporate Events

Holista Colltech Expands Share Base with New Issuance

Holista Colltech Limited announced the issuance of 32,785,714 fully paid ordinary shares as part of a placement disclosed on October 30, 2025. This move, made without the need for further disclosure under the Corporations Act, signifies the company’s compliance with relevant legal provisions and suggests a strategic effort to bolster its financial position and market presence.

Holista Colltech Limited Announces Cessation of Convertible Notes

Holista Colltech Limited announced the cessation of 1,105,262 convertible notes, effective June 16, 2025. This cessation may impact the company’s financial structure and investor relations, as convertible notes are often used for raising capital and can influence stock dilution and company valuation.

Holista Colltech Reports Strong Financial Performance and Growth in Supplement Division

Holista Colltech Limited reported a robust financial performance for the quarter ending September 2025, with customer receipts rising to $1.92 million, including a significant debt recovery. The company demonstrated improved cashflow discipline and cost management, resulting in a reduced net operating cash outflow of $78K. The supplement division showed strong growth, while collagen sales remained steady. The company’s liquidity position remains stable with a cash balance of $52K and unused credit facilities of $1.1 million.

Holista Colltech Announces Proposed Securities Issue to Bolster Growth

Holista Colltech Limited has announced a proposed issue of 32,785,714 ordinary fully paid securities, with a planned issue date of November 11, 2025. This move is part of a placement or other type of issue, which is expected to enhance the company’s capital base and support its growth initiatives. The announcement signifies Holista Colltech’s strategic efforts to strengthen its financial position and expand its market presence, potentially benefiting stakeholders through increased operational capabilities and market competitiveness.

Holista Colltech Secures $2.295 Million Investment to Strengthen Operations

Holista Colltech Limited has secured commitments to raise $2.295 million through the issuance of 32,785,714 shares at $0.07 each to two international investors. The funds will be used to support operational priorities, general working capital, and strengthen the company’s balance sheet, with the shares expected to be issued and quoted in early November 2025. This strategic move is anticipated to bolster Holista’s financial position, enabling it to continue its focus on delivering innovative health and wellness solutions.

Holista Colltech Reports Counterfeit Omega-3 Products in Malaysia

Holista Colltech Limited has reported to the Royal Malaysian Police about counterfeit PRISTIN® Omega-3 fish oil supplements sold on Lazada and Shopee in Malaysia. These counterfeit products, made from palm oil instead of fish-derived Omega-3, were identified after customer complaints and independent laboratory testing. Holista, a market leader in Malaysia for Omega-3 supplements, only sells its products through licensed pharmacies and its own webstores. The company plans to work with regulators and consumer groups to address the issue and reassure customers.